08th week of 2021 patent applcation highlights part 23 |
Patent application number | Title | Published |
20210054043 | MODULATION OF SLAMF6 SPLICE VARIANTS FOR CANCER THERAPY - The invention relates to cancer immunotherapy, particularly to improved therapeutic modalities involving specifically modulating the expression and/or activity of SLAMF6 splice variants. More specifically, embodiments of the invention provide compositions and methods for cancer therapy, including adoptive T cell transfer therapies, cell vaccines and/or polypeptide- based medicaments. In various embodiments, compositions and methods providing selective augmentation of SLAMF6 variant 3 (SLAMF6 | 2021-02-25 |
20210054044 | FC BINDING PROTEINS WITH CYSTEINE IN THE C-TERMINAL HELICAL REGION - The present invention relates to Fc binding proteins comprising one or more domains with Cysteine in the C-terminal helical region. The invention further relates to affinity matrices comprising the Fc binding proteins of the invention. The invention also relates to a use of these Fc binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Fc binding proteins of the invention. | 2021-02-25 |
20210054045 | PEPTIDES - The present invention relates to novel peptides derived from Nuclear receptor subfamily 0 group B member 1 (NR0B1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer. | 2021-02-25 |
20210054046 | METHODS AND COMPOSITIONS FOR MODIFICATION OF A HLA LOCUS - Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator. | 2021-02-25 |
20210054047 | NOVEL ANTICANCER FUSION PROTEIN AND USE THEREOF - The present invention relates to a novel anticancer fusion protein and use thereof, and more particularly, provides a fusion protein in which a tumor necrosis factor (TNF) superfamily protein is linked to a self-assembled protein, which is capable of forming a protein nanocage by self-assembly of the self-assembled protein. | 2021-02-25 |
20210054048 | RAPID AND SIMPLE PURIFICATION OF ELASTIN-LIKE POLYPEPTIDES DIRECTLY FROM WHOLE CELLS AND CELL LYSATES BY ORGANIC SOLVENT EXTRACTION - Disclosed herein is an optimized Elastin-like peptide purification scheme from whole cell lysate that is broadly applicable to neutral, acidic or basic ELP polypeptide. The method involves the use of one or more organic solvent to extract the ELP polypeptide from whole lysate followed by optional back extraction, precipitation, hot spins, and/or dialysis to purify the target ELP polypeptide. | 2021-02-25 |
20210054049 | VARIANT DOMAINS FOR MULTIMERIZING PROTEINS AND SEPARATION THEREOF - The current invention relates to means and methods for producing and isolating immunoglobulin proteins comprising a first and a second immunoglobulin polypeptide, in particular to means and methods for producing, and separating proteins comprising said first and second immunoglobulin polypeptide. By including variations to amino acids, and variant separation domains from a cell producing the desired immunoglobulin protein, a desired immunoglobulin protein as produced can be separated from mixtures of immunoglobulin proteins. | 2021-02-25 |
20210054050 | FORMULATION OPTIMIZATION FOR BISPECIFIC ANTIBODIES - The present invention provides methods and systems for formulation optimization of bispecific antibodies. The present application also provides methods and systems to select molecule candidates for constructing bispecific antibodies and formulation optimization thereof. Physico-chemical parameters of a bispecific antibody are characterized. The formulation optimization strategies are guided by the prediction of interaction parameters. Various formulation optimization strategies are provided based on these physico-chemical parameters. | 2021-02-25 |
20210054051 | METHODS FOR PURIFYING RECOMBINANT POLYPEPTIDES - A method of purifying a recombinant polypeptide from a Host Cell Protein (HCP), wherein the amino acid sequence of the recombinant polypeptide comprises a cathepsin L cleavage site is provided. The method includes: (a) applying a solution containing the recombinant polypeptide and HCP to a superantigen chromatography solid support, (b) washing the superantigen chromatography solid support with a wash buffer containing caprylate and arginine; and (c) eluting the recombinant polypeptide from the superantigen chromatography solid support. A method of purifying an anti-OX40 antigen binding polypeptide from a Host Cell Protein (HCP) is also provided. | 2021-02-25 |
20210054052 | RECOMBINANT HERPES SIMPLEX VIRUS HAVING EXPRESSION CASSETTE EXPRESSING FUSED PROTEIN OF CANCER CELL-TARGETING DOMAIN AND EXTRACELLULAR DOMAIN OF HVEM AND USE THEREOF - The present invention relates to a recombinant herpes simplex virus (HSV) containing an expression cassette capable of expressing a fused protein of a cancer-cell-targeting domain and an extracellular domain of HVEM and the use thereof. When the recombinant HSV infects and enters target cells, which are cancer cells, HSV proliferates, and an adapter, which is the fused protein, is expressed in the cells and is released to the outside of the cells along with the proliferated HSV virion upon cell lysis, or is released even before the virion is released due to cell lysis when the adapter contains a leader sequence, and the fused protein released to the outside of the cells acts to induce the HSV virion to infect surrounding cancer cells expressing a target molecule recognized by the cancer-cell-targeting domain or to increase the infection efficiency thereof. | 2021-02-25 |
20210054053 | FORMULATIONS OF ANTIBODY MOLECULES TO INFLUENZA VIRUS - This disclosure relates to formulations of peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use. | 2021-02-25 |
20210054054 | ENGINEERING PH-DEPENDENT ANTIGEN BINDING ACTIVITY INTO ANTI-HIV ANTIBODIES WITH IMPROVED PHARMACOKINETICS - The disclosure is directed to a histidine-mutated anti-HIV antibody having one or more mutations at the residue Y53a, D58, K96, D97, N98, or T100a in the heavy chain of ibalizumab, and at the residue S26, L30, L33, Q89, Y92, S93 or Y94 in the light chain of ibalizumab. In addition, the disclosure also is directed to two histidine mutated variants with two mutations, one with mutations at the residues Y53a and Y94, and the other with mutations at the residues D58 and L30 in the heavy and light chains of ibalizumab, respectively. | 2021-02-25 |
20210054055 | HIGHLY SPECIFIC ZIKA NEUTRALIZING HUMAN ANTIBODIES - Provided herein, in some embodiments, are compositions of Zika-specific antibodies and antigen-binding fragments thereof and methods of using said antibodies and antigen-binding fragments. | 2021-02-25 |
20210054056 | HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF - Provided herein are antibodies that bind Fagales allergens, Fagales related allergens, birch pollen, or Bet v 1, compositions comprising the antibodies, nucleic acids encoding the antibodies, and methods of using the antibodies. According to certain embodiments, the antibodies are fully human monoclonal antibodies that bind to Bet v 1. The antibodies are useful for binding Bet v 1 in vivo, thus preventing binding of the allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the Fagales allergens in sensitized individuals. | 2021-02-25 |
20210054057 | AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY - The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy. | 2021-02-25 |
20210054058 | METHODS TO PRODUCE A HUMAN PLASMA-DERIVED IGG PREPARATION ENRICHED IN BRAIN DISEASE-RELATED NATURAL IGGS - The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies), are also provided. | 2021-02-25 |
20210054059 | FACTOR H POTENTIATING ANTIBODIES AND USES THEREOF - The invention relates to novel isolated, synthetic or recombinant antibodies and fragments thereof specific for factor H. The invention further relates to the use of such antibodies and fragments for inhibiting complement activation and treatment of disorders associated with complement activation. | 2021-02-25 |
20210054060 | MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15) - The present invention relates to novel monoclonal anti-human-GDF-15 antibodies, pharmaceutical compositions, kits, methods and uses and the cell lines capable of producing the monoclonal antibodies described herein. The present invention further relates to novel antibodies to human GDF-15 capable of inhibiting cancer growth. | 2021-02-25 |
20210054061 | ANTI-S100A8/A9 ANTIBODY AND USE THEREOF - Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor. | 2021-02-25 |
20210054062 | ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF - The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Ina specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5. | 2021-02-25 |
20210054063 | COMBINATION THERAPY WITH ANTI-IL-8 ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TREATING CANCER - Provided herein are methods for the clinical treatment of tumors (e.g., advanced solid tumors) in patients having certain levels of serum IL-8 using an anti-IL-8 antibody in combination with an anti-PD-1 antibody. | 2021-02-25 |
20210054064 | ANTAGONISTS OF IL-33 FOR USE IN METHODS FOR PREVENTING ISCHEMIA REPERFUSION INJUSRY IN AN ORGAN - Inflammation is a prominent feature of ischemia-reperfusion injury (IRI) characterized by leukocyte infiltration and renal tubular injury. However, the signals that initiate these events remain poorly understood. The inventors identify the nuclear alarmin interleukin (IL)-33 as an initiation factor of tissue injury and also as a major amplification factor of the innate immune response triggered by experimental kidney ischemia-reperfusion in mice. In mice lacking IL-33, IRI is reduced, as attested by early decreased tubular cell injury, and by subsequent decreased infiltration of IFN-γ/IL-17A-producing neutrophils and preservation of renal functions. These findings led the inventors to propose that endogenous IFN-33 contributes to kidney IRI by promoting iNKT cell recruitment and cytokine production, resulting in neutrophil infiltration and activation at the injury site. Accordingly, the present invention relates to antagonists of IL-33 for use in methods for preventing ischemia reperfusion injury in an organ. | 2021-02-25 |
20210054065 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF - The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed. | 2021-02-25 |
20210054066 | ANTI-INTERFERON GAMMA ANTIBODIES AND USES THEREOF - Provided is an anti-INF-γ antibody. Also provided are a composition comprising the antibody and a pharmaceutical application of the antibody in treating IFN-γ mediated syndrome. | 2021-02-25 |
20210054067 | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF - Antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas. | 2021-02-25 |
20210054068 | DETECTION OF PANCREATIC CANCER WITH AN ENGINEERED ANTI-THY1 SINGLE-CHAIN ANTIBODY - Compositions and methods for detection and diagnosis of pancreatic cancer are disclosed. An engineered anti-thymocyte differentiation antigen 1 (Thy1) single-chain antibody and bioconjugates thereof can be used for detecting and diagnosing pancreatic adenocarcinoma. The anti-Thy1 single-chain antibody selectively binds to the Thy1 antigen, which is overexpressed on pancreatic tumor neovasculature and precancerous lesions, and is capable of detecting pancreatic cancer even at the earliest stages of the disease. Thy1-targeted diagnostic agents can be produced by conjugation of the anti-Thy1 single-chain antibody to various diagnostic agents, such as contrast agents, photoactive agents, or detectable labels that are useful for detection and medical imaging of pancreatic tumors. | 2021-02-25 |
20210054069 | TREM2 Antigen Binding Proteins And Uses Thereof - The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described. | 2021-02-25 |
20210054070 | ANTI-CD47 ANTIBODIES AND USES THEREOF - Provided herein are compositions, methods and uses involving antibodies that specifically bind to human CD47. Also provided are uses and methods, such as therapeutic methods, diagnostic methods, and methods of making such antibodies. | 2021-02-25 |
20210054071 | SINGLE-DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST TIGIT - Provided are constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes TIGIT. Also provided are methods of making and using these constructs. | 2021-02-25 |
20210054072 | ANTI-SIGLEC-7 ANTIBODIES HAVING REDUCED EFFECTOR FUNCTION - The invention provides methods and compositions for the treatment of cancer using anti-Siglec-7 antibodies that have reduced effector function. | 2021-02-25 |
20210054073 | ANTI-PD-L1 ANTIBODIES AND USES THEREOF - The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer. | 2021-02-25 |
20210054074 | ANTI-LAG-3 ANTIBODIES AND METHODS OF USE THEREOF - The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies. | 2021-02-25 |
20210054075 | MONOCLONAL ANTIBODIES TARGETING KILLER IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) FAMILY SIGNALING - Monoclonal antibodies derived from the native human repertoire that bind the extracellular portion of Killer IgG Receptor (KIR) and pharmaceutical and veterinary compositions thereof are useful in treating cancer in human and other subjects. | 2021-02-25 |
20210054076 | CYTOTOXICITY-INDUCING THERAPEUTIC AGENT - The present inventors discovered novel multispecific antigen-binding molecules with excellent cellular cytotoxicity and high stability, which comprise a first domain comprising a first antibody variable region that binds to Claudin 6, a second domain comprising a second antibody variable region that binds to T cell receptor complex. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing Claudin 6, it is possible to produce novel pharmaceutical compositions comprising the multispecific antigen-binding molecules for treating or preventing various cancers. | 2021-02-25 |
20210054077 | CD3 ANTIGEN BINDING FRAGMENTS AND COMPOSITIONS COMPRISING SAME - This disclosure relates to compositions having an antibody binding fragment that specifically binds to CD3 or an epitope thereof. Some embodiments include compositions and antibody binding fragments with increased stability. Bispecific fusion proteins including such antibody-binding fragments are also disclosed. | 2021-02-25 |
20210054078 | ANTI-PD-L1 ANTIBODY AND USE THEREOF - Disclosed are an anti-PD-L1 antibody or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, a pharmaceutical composition for preventing or treating cancer containing the same, and a composition for co-administration with an antibody other than an antibody binding to PD-L1, containing the same. | 2021-02-25 |
20210054079 | FORMULATIONS OF HUMAN ANTI-PD-LI ANTIBODIES - This disclosure relates to formulations and compositions of an antibody directed against human anti-PD-L1, such as durvalumab. | 2021-02-25 |
20210054080 | PEPTIDES - The present invention relates to novel peptides derived from Zinc transporter 8 (SLC30A8), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer. | 2021-02-25 |
20210054081 | ANTI HLA-G SPECIFIC ANTIBODIES - The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the α3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies. | 2021-02-25 |
20210054082 | ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR - Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described. | 2021-02-25 |
20210054083 | EXPRESSION VECTOR ORGANIZATION, NOVEL PRODUCTION CELL GENERATION METHODS AND THEIR USE FOR THE RECOMBINANT PRODUCTION OF POLYPEPTIDES - Herein is reported an expression vector comprising —an antibody light chain expression cassette, —an antibody heavy chain expression cassette, and —a selection marker expression cassette, wherein the expression cassettes are arranged unidirectional, and wherein the expression cassettes are arranged in the 5′ to 3′ sequence of antibody heavy chain expression cassette, antibody light chain expression cassette and selection marker expression cassette. Further are reported herein methods for the generation of antibody producing cells and the use of these cells for the recombinant production of antibodies. | 2021-02-25 |
20210054084 | ANTI-CD25 ANTIBODY AGENTS - The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in 5 pharmaceutical compositions and methods of treatment, in particular for treating cancer. | 2021-02-25 |
20210054085 | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRB ANTIBODY - The present invention provides, among other things, methods of treating pruritic or inflammatory skin diseases or disorders, or pruritus associated with a disease or disorder, with an anti-OSMRβ antibody, including methods of treating pruritus, associated with atopic dermatitis, chronic kidney disease-associated pruritus, uremic pruritus or prurigo nodularis, chronic idiopathic pruritus, chronic idiopathic urticaria, chronic spontaneous urticaria, cutaneous amyloidosis, lichen simplex chronicus, plaque psoriasis, lichens planus, inflammatory ichthyosis, mastocytosis and bullous pemphigoid, comprising a step of administering to a subject in need of treatment an anti-OSMRβ antibody at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of the disease or disorder relative to a control. | 2021-02-25 |
20210054086 | IMMUNE CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR - Described herein are methods for producing and utilizing T cells comprising chimeric antigen receptors (CAR) comprising two or more extracellular domains, each comprising a portion of the extracellular domain of a Tumor Necrosis Factor (TNF) superfamily receptor ligand, e.g., A PRoliferation-Inducing Ligand (APRIL). The CARs described herein are capable of targeting, e.g., B cell maturation antigen (BCMA) and/or transmembrane activator and CAML interactor (TACI). Additionally, the CAR T cells of this present invention overcome resistance to anti-BCMA targeted therapies and utilize dimerizing and trimerizing transmembrane domains for optimal function. Further, this invention is related to methods of treating cancer (e.g., multiple myeloma (MM)), plasma cell diseases or disorders, autoimmune diseases or disorders, or transplant rejection. | 2021-02-25 |
20210054087 | THERAPEUTIC ANTIBODIES AND THEIR USES - The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided. | 2021-02-25 |
20210054088 | ANTI-CD137 ANTIBODIES FOR COMBINATION WITH ANTI-PD-L1 ANTIBODIES - The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with anti-human PD-L1 antibodies, chemotherapy, and ionizing radiation. | 2021-02-25 |
20210054089 | ANTI-CD137 ANTIBODIES FOR COMBINATION WITH ANTI-PD-1 ANTIBODIES - The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with anti-human PD-1 antibodies, chemotherapy, and ionizing radiation. | 2021-02-25 |
20210054090 | ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES AND USES THEREOF - The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided. | 2021-02-25 |
20210054091 | ANTIBODIES TO CD40 - Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof. | 2021-02-25 |
20210054092 | HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONS - The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided. | 2021-02-25 |
20210054093 | Novel CD47 Monoclonal Antibodies and Uses Thereof - The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation. | 2021-02-25 |
20210054094 | ANTIBODIES BINDING TO GPRC5D - The present invention generally relates to antibodies that bind to GPRC5D, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease. | 2021-02-25 |
20210054095 | Antibodies To Tumour Antigens - The present application relates to specific binding members that bind carbonic anhydrase IX (CAIX). In particular, the present application relates to the treatment, diagnosis and detection of tumours, e.g. solid tumours, using specific binding members that bind CAIX. The specific binding member may be conjugated to a biocidal or cytotoxic molecule, or to a detectable label. | 2021-02-25 |
20210054096 | COMBINATION OF AN ERBB-2/ERBB-3 BISPECIFIC ANTIBODY WITH ENDOCRINE THERAPY FOR BREAST CANCER - The invention relates to methods of treating of subject that has breast cancer or is at risk of having said cancer, comprising administering to the subject in need thereof a combination of a therapeutically effective amount of an ErbB-2/ErbB-3 bispecific antibody and a therapeutically effective amount of an endocrine therapy drug, wherein the bispecific antibody has an antigen binding site that can bind an extra-cellular part of ErbB-2 and an antigen binding site that can bind an extra-cellular part of ErbB-3; and to means for said method. | 2021-02-25 |
20210054097 | FACTOR X BINDERS ENHANCING FX ACTIVATION - The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia. | 2021-02-25 |
20210054098 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. | 2021-02-25 |
20210054099 | COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION - The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation. | 2021-02-25 |
20210054100 | STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES - The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months. | 2021-02-25 |
20210054101 | ANTIBODIES TO MATRIX METALLOPROTEINASE 9 - The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof). | 2021-02-25 |
20210054102 | COMPOSITIONS AND METHODS FOR ENHANCING NUCLEAR TRANSLOCATION - Amino acid sequences capable of enhancing nuclear translocation are provided. Also referred to a nuclear localization signals (NLS) the sequences can be linked to or grafted into antibodies or fragments or fusion proteins thereof to enhance nuclear translocation of the antibody. Compositions and antibodies including an NLS conjugated or otherwise linked directly or indirectly to an active agent cargo are also provided. Exemplary cargo includes proteins, peptides, carbohydrates, polysaccharides, nucleic acid molecules, inorganic molecules, organic molecules, and diagnostic agents. Pharmaceutical compositions further including a pharmaceutically acceptable carrier are also provided. Methods of delivering the composition or antibody alone or with a cargo linked thereto to the nucleus of cell, methods of selecting or screening for compositions having a desired cellular activity, and methods of treating diseases and disorders are also provided. | 2021-02-25 |
20210054103 | IgG Bispecific Antibodies and Processes for Preparation - The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (C | 2021-02-25 |
20210054104 | A PROCESS FOR THE PREPARATION OF ESSENTIAL OILS MODIFIED NANOCELLULOSE AND APPLICATION THEREOF - The present invention provides a process for the preparation of essential oil modified nanocellulose and applications thereof. The invention further provides a process wherein the essential oil is covalently bonded with the nanocellulose such that the essential oil does not leach out. The edible coatings comprising the developed essential oil modified nanocellulose thus exhibit a prolonged antimicrobial effect. | 2021-02-25 |
20210054105 | AQUEOUS IRON CARBOHYDRATE COMPLEXES, THEIR PRODUCTION AND MEDICAMENTS CONTAINING THEM - A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, a process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions. | 2021-02-25 |
20210054106 | OMNIPHILIC NANO-VESICLES BASED ON MODIFIED POLYSACCHARIDES FOR DELIVERY OF ACTIVE AGENTS - The present invention relates to modified polysaccharide-based self-assembled aggregates capable to encapsulate and deliver active agents into and between media of different hydrophilicity/hydrophobicity. | 2021-02-25 |
20210054107 | EXTRACTION METHOD OF CHITIN NANOCRYSTALS USING ELECTRON BEAM IRRADIATION AND CHITIN NANOCRYSTAL POWDER - The present disclosure relates to a method for extracting chitin nanocrystals through electron beam irradiation comprising the steps of: (i) irradiating a chitin-based solid material with an electron beam; (ii) washing the chitin-based solid material subjected to electron beam irradiation; (iii) adding a basic solution to the washed chitin-based solid material; (iv) high-pressure homogenizing the chitin-based solid material dispersed in an aqueous system to which the basic solution is added, to prepare a suspension containing chitin nanocrystals. | 2021-02-25 |
20210054108 | DERIVATIVES OF N-DESULFATED GLYCOSAMINOGLYCANS AND USE AS DRIGS - A glycosaminoglycan derivative which is obtainable by a process that includes the steps of N-desulfation of from 25% to 100% of the N-sulfated residues of a glycosaminoglycan, and oxidation, by periodate at a pH of from 5.5 to 10.0, of from 25% to 100% of the 2-N-, 3-O-non-sulfated glucosamine residues, and of the 2-O-non-sulfated uronic acid residues of said glycosaminoglycan, under conditions effective to convert adjacent diols and adjacent OH/NH | 2021-02-25 |
20210054109 | Process for Making and Using a Composition of Matter - A process for making a composition of matter that includes the steps of preparing an aqueous phase and an oil phase, and emulsifying the aqueous phase and the oil phase together to form a water-in-oil emulsification. The water-in-oil emulsification is then homogenized or otherwise processed to form an emulsification product, followed by the step of initiating a polymerization reaction of the emulsification product to form a polymerization reaction product. Lastly, the process includes inverting or otherwise processing the polymerization product to form the composition of matter having: 15-25% oil phase; 35-50% water; 20-35% polymer; 0-10% surfactant; and 0-3% other trace materials. | 2021-02-25 |
20210054110 | POSS-TX NANO-PHOTO-INITIATOR SYNTHESIS AND IN SITU PHOTOCHEMICAL AG NANO-PARTICLE SYNTHESIS WITH THE HELP OF POSS-TX AND WRINKLED SURFACE FORMATION - The present invention particularly relates to synthesizing photo-initiators having poly-oligo-silsesquioxane (POSS) structure and realizing photo-polymerization by using these photo-initiators and simultaneous and in-situ synthesis of Ag nano-particles in polymer matrix comprising POSS structure and obtaining wrinkled surfaces as a result of self-arranging thereof. | 2021-02-25 |
20210054111 | Mixed Catalyst Systems Containing Bridged Metallocenes with a Pendant Group 13 Element, Processes for Making a Polymer Product Using Same, and Products Made from Same - A mixed metallocene catalyst system can comprise at least one metallocene catalyst compound comprising a structure represented by formula (A) below and optionally at least one other metallocene catalyst compound having a structure represented by formula (B) below: | 2021-02-25 |
20210054112 | Surfactant as Titanation Ligand - A method comprising contacting a silica support with a titanium-containing solution to form a titanated silica support, wherein the titanium-containing solution comprises a titanium compound, a solvent, and a surfactant. | 2021-02-25 |
20210054113 | ACRYLIC POLYMER COAGULATES - The present invention provides a multilayered acrylic polymer coagulate characterized in that the coagulate has a bulk density of 0.3 to 0.6 g/cm | 2021-02-25 |
20210054114 | Method for Preparing 2-Cyanoethyl Group-Containing Polymer - A method for preparing a 2-cyanoethyl group-containing polymer is provided. The method can prepare a purified 2-cyanoethyl group-containing polymer with high purity even while a reduced amount of water was used during the purification process, thus reducing the amount of wastewater generated. | 2021-02-25 |
20210054115 | SYSTEM AND METHOD FOR PROCESSING GUAYULE RUBBER - A guayule rubber processing system and method involves mixing a guayule rubber and at least one solvent blend in an extruder, in order to remove resin found in the guayule miscella and to precipitate the guayule miscella to form a precipitate. The at least one solvent blend has a first solvent configured to precipitate the guayule rubber, and a second solvent configured to swell the resulting precipitate. In particular, a series of the solvent blends may be used at different locations along a length of the extruder and may further include distinct blends of the first solvent and the second solvent, introduced at the different locations, and having different ratios of the first solvent and the second solvent. | 2021-02-25 |
20210054116 | MODIFIED POLYISOBUTYLENE POLYMER FOR RUBBER COMPOUNDING AND RUBBER COMPOSITION COMPRISING SAME - The present invention relates to a modified polyisobutylene polymer for rubber compounding including polyisobutylene having isobutylene as a main chain, unsaturated dicarboxylic anhydride, and a silane compound, and more particularly, 20 to 80 wt % of polyisobutylene having isobutylene as a main chain, 1 to 20 wt % of unsaturated dicarboxylic anhydride, and 1 to 60 wt % of a silane compound. In particular, when the polyisobutylene polymer of the present invention is used as an additive for rubber, the dispersibility of a filler can be significantly increased and both grip performance and rolling resistance can be improved. | 2021-02-25 |
20210054117 | METHOD FOR PRODUCING COPOLYMER OF POLAR GROUP-CONTAINING ALLYL MONOMER - The present invention relates to a method for producing a copolymer of ethylene and an allyl monomer that is represented by formula (1) and has a polar group, or a copolymer of ethylene, the allyl monomer that is represented by formula (1) and has a polar group, and another monomer. This production method is characterized by using a metal complex, which is represented by general formula (C1), as a polymerization catalyst and by having a silane compound, which is represented by general formula (2) and has a silicon-hydrogen bond, coexist with the metal complex. (In the formulae, the symbols are as defined in the description.) According to the present invention, a copolymer of an allyl monomer that has a polar group is able to be produced with high catalytic activity, said copolymer being capable of having various applications. | 2021-02-25 |
20210054118 | COPOLYMER OF ETHYLENE AND A 1,3-DIENE - A copolymer of ethylene and of a 1,3-diene of formula CH | 2021-02-25 |
20210054119 | OLEFIN POLYMERIZATION ACTIVATORS - Embodiments of this disclosure include processes of polymerizing olefins, the process comprising contacting ethylene and a (C | 2021-02-25 |
20210054120 | Hybrid Supported Metallocene Catalyst and Method for Preparing Olefin Polymer Using the Same - A catalyst composition, a method from preparing an olefin polymer using the same, and an olefin polymer prepared from the same are disclosed herein. In some embodiments, a catalyst composition includes a first metallocene compound represented by the Chemical Formula 1, a second metallocene compound represented by the Chemical Formula 2, and a support. The catalyst composition can exhibit high activity in an olefin polymerization reaction and thus contribute to reducing catalyst costs, and can also exhibit high copolymerizability which can secure excellent processability and long-term physical properties, and thus, is suitable for providing polymers for pipes. | 2021-02-25 |
20210054121 | Methods for Scale-Up From a Pilot Plant to a Larger Production Facility - Methods for scale-up from a pilot plant to a larger production facility of a bimodal polymer product having a density, a melt index and melt index ration are provided herein. | 2021-02-25 |
20210054122 | PRODUCING POLYOLEFIN PRODUCTS - A polymerization catalyst system, a method of using the polymerization catalyst system, and a polymer produced with the catalyst system. The polymerization catalyst system has a non-metallocene catalyst and a metallocene catalyst. The metallocene catalyst has the formula: | 2021-02-25 |
20210054123 | POLYOLEFIN PRODUCTION WITH CHROMIUM-BASED CATALYSTS - A system and method for charging a chromium-based catalyst to a mix vessel; introducing a reducing agent through an entrance arrangement into the mix vessel, and agitating a mixture of the chromium-based catalyst, the reducing agent, and a solvent in the mix vessel to promote contact of the reducing agent with the chromium-based catalyst to give a reduced chromium-based catalyst. | 2021-02-25 |
20210054124 | METHOD FOR PREPARING THERMOPLASTIC COPOLYMER, THERMOPLASTIC COPOLYMER PREPARED THEREFROM, AND THERMOPLASTIC RESIN COMPOSITION INCLUDING THE SAME - The present invention relates to a method for preparing a thermoplastic copolymer using monomer droplets, a thermoplastic copolymer prepared therefrom and a thermoplastic resin composition including the same. In the preparation method, monomer droplets including an aromatic vinyl-based monomer are injected after reaching a polymerization conversion ratio of 10% to participate in the reaction after initiating polymerization, and a thermoplastic copolymer having an increased average particle diameter may be prepared in high yield. | 2021-02-25 |
20210054125 | METHOD FOR PRODUCING AN OBJECT FROM A PRECURSOR, AND USE OF A RADICALLY CROSS-LINKABLE RESIN IN AN ADDITIVE PRODUCTION METHOD - The invention relates to a method for producing an object from a precursor, comprising the steps: I) depositing a radically cross-linked resin on a carrier so that a layer of a construction material connected to the carrier is obtained, said layer corresponding to a first selected cross-section of the precursor; II) depositing a radically cross-linked resin on a previously applied layer of the construction material so that an additional layer of the construction material is obtained, which corresponds to a further selected cross-section of the precursor and which is connected to the previously applied layer; III) repeating step II) until the precursor is formed, wherein, at least in step II), the deposition of a radically cross-linked resin is carried out by allowing energy to act on a selected region of a radically cross-linkable resin, corresponding to the respectively selected cross-section of the object, wherein the radically cross-linkable resin has a viscosity (23° C., DIN EN ISO 2884-1) of =5 mPas to =100000 mPas. The radically cross-linkable resin comprises a curable component, in which NCO groups which are blocked with a blocking agent, compounds having at least two Zerewitinoff-active H atoms and olefinic C═C double bonds are present, wherein the blocking agent is an isocyanate or the blocking agent is selected in such a manner that, after deblocking of the NCO group, no release of the blocking agent as a free molecule or as a part of other molecules or molecule parts occurs. Following step III), step IV) is carried out: IV) treating the precursor obtained according to step III) under conditions which are sufficient to at least partially deblock NCO groups which are present in the radically cross-linked resin of the obtained precursor, and to react the resulting functional groups with compounds having at least two Zerewitinoff-active H atoms, with the result that the object is obtained. | 2021-02-25 |
20210054126 | POLYMERIZABLE COMPOSITION FOR OPTICAL MATERIAL AND MOLDED PRODUCT - A polymerizable composition for an optical material of the present invention includes (A) an allyl carbonate compound represented by General Formula (1) and including two or more allyloxycarbonyl groups; (B) a (meth) acrylate compound represented by General Formula (2) and including two or more (meth) acryl groups; and (C) a photochromic compound, in which, in 100% by weight in a total of the compound (A) and the compound (B), the compound (A) is included in an amount of more than 0% by weight and 30% by weight or less and the compound (B) is included in an amount of 70% by weight or more and less than 100% by weight. | 2021-02-25 |
20210054127 | FREESTANDING ION GEL AND METHOD FOR PREPARING THE SAME - Disclosed is preparation of a freestanding ion gel having high stability and high ionic conductivity based on surface-activity ionic liquids. Further, disclosed is a solid electrolyte using the ion gel. A method for preparing the freestanding ion gel include mixing a surface-activity ionic liquid having an alkyl group having 8 or greater carbon atoms, a crosslinking agent, water and oil with each other to form a bicontinuous microemulsion mixture; ii) adding an initiator to the mixture; and iii) curing the mixture using ultraviolet (UV) or thermal energy to form a freestanding ion gel. | 2021-02-25 |
20210054128 | Synthesis Of Low Molecular Weight Tapered Styrene-Butadiene Copolymer And Its Use In Tires - Methods are described for the preparation of tapered styrene-butadiene copolymers for use as partial or full oil replacements in rubber compositions. The resulting rubber compositions exhibit improved storage modulus and wear resistance properties. | 2021-02-25 |
20210054129 | COMPOSITION AND METHOD FOR LAMINATION OF SILICON DOMINANT ELECTRODES - Disclosed are maleic anhydride-grafted cyclic olefin copolymers, methods for preparing maleic anhydride-grafted cyclic olefin copolymers, low temperature methods for laminating anodes comprising the maleic anhydride-grafted cyclic olefin copolymers, and anodes and alkali ion batteries that comprise the maleic anhydride-grafted cyclic olefin copolymers. | 2021-02-25 |
20210054130 | POLYMER COMPOSITION, METHOD OF PRODUCING CYANO GROUP-CONTAINING POLYMER, AND CYANO GROUP-CONTAINING POLYMER COMPOSITION - A cyano group-containing polymer is produced using a polymer composition including an olefinic double bond-containing polymer, cyano group-containing compound represented by the following Formula (1): | 2021-02-25 |
20210054131 | LAMINATED FILM, METHOD FOR PRODUCING SAME, AND POLARIZING PLATE - A layered film includes first, second, and third layers formed of first, second, and third resins, respectively, and provided in this order. The second resin contains an alkoxysilyl group-modified product of a hydrogenated product of a block copolymer; has 0.020% by weight or less of a moisture content as measured by the Karl-Fischer method after immersed in water at 37° C. for 24 hours and then allowed to stand at 23° C. and a humidity of 70% for 24 hours; and has a flexural modulus lower than flexural moduli of the first and third resins. One or both of the first and third resins contain a polymer containing an alicyclic structure. The first resin has a specific water vapor transmission rate. A ratio of a sum of thicknesses of the first and third layers relative to a thickness of the second layer is in a specific range. | 2021-02-25 |
20210054132 | POLYURETHANES HAVING LOW EMISSIONS OF ORGANIC COMPOUNDS - The present disclosure relates to a process for producing polyurethanes including mixing (a) polyisocyanate, (b) polymeric compounds having isocyanate-reactive groups, (c) catalysts and optionally (d) blowing agents, (e) chain-extending and/or crosslinking agents and (f) auxiliaries and/or additives to afford a reaction mixture and reacting the reaction mixture to afford polyurethane. The polymeric compounds having isocyanate-reactive groups (b) are a polyesterol (b1) obtainable by polycondensation of an acid component with an alcohol component. The acid component includes malonic acid and/or derivatives thereof and the alcohol component includes an aliphatic dialcohol having 4 to 12 carbon atoms. The present disclosure further relates to a polyurethane obtainable by such a process and to a method of using in enclosed spaces. | 2021-02-25 |
20210054133 | CURED EPOXY RESIN MATERIAL, EPOXY RESIN COMPOSITION, MOLDED ARTICLE, AND COMPOSITE MATERIAL - A cured epoxy resin, which is a cured product of an epoxy compound having a mesogenic structure and a curing agent having a molecular chain or a flexible backbone with a molecular weight of 100 or more, the cured epoxy resin having a smectic structure; a cured epoxy resin, which is a cured product of an epoxy compound having a mesogenic structure and a curing agent having a molecular chain or a flexible backbone with a molecular weight of 100 or more, the cured epoxy resin not having a smectic structure; an epoxy resin composition, comprising an epoxy compound having a mesogenic structure and a curing agent having a molecular chain with a molecular weight of 100 or more; and an epoxy resin composition, comprising an epoxy compound having a mesogenic structure and a curing agent having a flexible backbone with a molecular weight of 100 or more. | 2021-02-25 |
20210054134 | CYCLOALIPHATIC AMINES FOR EPOXY FORMULATIONS: A NOVEL CURING AGENT FOR EPOXY SYSTEMS - The present invention related to an epoxy curing agent comprising a first amine component and a second amine component. The present invention also relates to an epoxy resin system containing the reaction product of an epoxy resin component and an amine-based curing agent component comprising a first amine component and a second amine component. The present invention also relates to a method for producing the epoxy resin system comprising combining an epoxy resin component with an amine-based curing agent component, the amine-based curing agent component comprising a first amine component and a second amine component; and reacting the amine-based curing agent component and the epoxy resin component to form a cured epoxy resin composition. The first amine component is N-(3-aminopropyl) cyclohexylamine. The second amine component is the hydrogenated product of oligomeric structure from the 4,4′-Methylenedianiline process. N-(3-aminopropyl) cyclohexylamine enhances desirable properties of epoxy resin compositions without the negative impact on mechanical properties in the cured product normally seen with cycloaliphatic amine-based curing agents. | 2021-02-25 |
20210054135 | CURING AGENT FOR WATER-BASED EPOXY RESIN, WATER-BASED EPOXY RESIN COMPOSITION, AND CURED PRODUCT THEREOF - Provided is a curing agent for a water-based epoxy resin, which contains the following component (A) and component (B):
| 2021-02-25 |
20210054136 | EPOXY POLYMER, EPOXY RESIN, EPOXY RESIN COMPOSITION, RESIN SHEET, B-STAGE SHEET, CURED PRODUCT, C-STAGE SHEET, METAL FOIL WITH RESIN, METAL SUBSTRATE AND METHOD FOR MANUFACTURING EPOXY RESIN - Provided is an epoxy polymer which has a mesogen skeleton and a structural unit represented by Formula (A). In Formula (A), each R | 2021-02-25 |
20210054137 | RESIN COMPOSITION FOR FIBER-REINFORCED COMPOSITE MATERIALS, AND FIBER-REINFORCED COMPOSITE MATERIAL USING SAME - The present invention has an object to provide a resin composition for fiber-reinforced composite materials that excels in rapid curability without impairing low viscosity and heat resistance. A two-component curable resin for fiber-reinforced composite materials is provided, which is configured of a base material including an epoxy resin (A) and a curing agent including an amine compound (B) selected from either norbornane diamine or triethylenetetramine and a phenol compound (C), and in which a mass ratio of the base material to the curing agent is within the range of from 90:10 to 70:30, and the phenol compound (C) includes a phenol compound including two or more phenolic hydroxyl groups and is contained at 5% by weight to 35% by weight in the curing agent. A fiber-reinforced composite material is obtained by mixing reinforcing fibers in the resin composition for fiber-reinforced composite materials. | 2021-02-25 |
20210054138 | POLYPHENYLENE COMPOUND - This is to provide a non-halogen containing compound excellent in proton conductivity and capable of suitably being used for a polymer electrolytic fuel cell | 2021-02-25 |
20210054139 | RING OPENING POLYMERIZATION IN AN AQUEOUS DISPERSION - We have developed a ring opening polymerization method in an aqueous dispersion for the formation of latex. By encapsulating a catalyst in micelles dispersed in water, a seeded catalytic polymerization of various monomers in water was successfully performed. An amphiphilic molecule was used to form a micelle with a hydrophobic core in water. The catalyst that was encapsulated within this structure and the formed microcapsules were used as microreactors for the formation of biodegradable elastomers. | 2021-02-25 |
20210054140 | POLYESTER FILM AND METHOD FOR REPRODUCING POLYESTER CONTAINER USING SAME - The embodiments relate to a polyester film, which comprises a copolymerized polyester resin comprising a diol component and a dicarboxylic acid component and has a heat shrinkage rate of 30% or more in the main shrinkage direction upon thermal treatment at a temperature of 80° C. for 10 seconds and a melting point of 170° C. or higher as measured by differential scanning calorimetry, which not only solve the environmental problems by improving the recyclability of the polyester container, but also are capable of enhancing the yield and productivity, and a process for regenerating a polyester container using the same. | 2021-02-25 |
20210054141 | Advanced Processing of Absorbable Poly(p-dioxanone) Containing High Level of p-Dioxanone Monomer - The present invention is directed methods of making absorbable poly(p-dioxanone) pellets by melt polymerization of p-dioxanone conducted in a single reactor with a temperature regulator by charging a melt reactor with a mixture of p-dioxanone (PDO) monomer, initiator, catalyst, and optionally a dye; melt polymerizing the mixture in the melt reactor with sufficient agitation of the mixture to allow complete mixing of the monomer and for sufficient time to form a PDO polymer product having an unreacted PDO monomer content of at least 65 mole percent; placing the PDO polymer product under a vacuum to remove at least portion of unreacted PDO; discharging the PDO polymer product from the melt reactor directly into an in-line, underwater pelletizer to produce undried PDO pellets, collecting the undried PDO pellets, and storing the collected PDO pellets in the freezer or a vacuum chamber prior to drying. | 2021-02-25 |
20210054142 | AROMATIC POLYCARBONATE OLIGOMER SOLID - The purpose of the present invention is to provide an aromatic polycarbonate oligomer solid with substantially reduced low-molecular-weight components, no or a substantially reduced amount of chlorine-containing compounds, high loose bulk density, and ease of handling. The aromatic polycarbonate oligomer solid contains a repeating unit represented by general formula (1), has a weight average molecular weight of 500 to 10000, low-molecular-weight components less than or equal to 5.0 area % measured with high-speed liquid chromatography, and a loose bulk density of greater than or equal to 0.30 g/cm | 2021-02-25 |